Introduction
(ii) is intraperitoneal insulin administration more convenient than the subcutaneous route?; (iii) is there any benefit to using alternative non-glucose osmotic Since the introduction of continuous ambulatory periagents?; and (iv) is peritoneal dialysis the preferred toneal dialysis (CAPD) to clinical practice, this modalmodality in diabetic patients? ity of end-stage renal disease treatment has appeared as an appealing dialysis procedure for patients with insulin-dependent (IDDM ) and non-insulin-dependent Infections (NIDDM ) diabetes mellitus. Furthermore, since the early 1980s, patients' survival has been so encouraging Peritonitis is one of the major causes of morbidity in that CAPD has become the preferred mode of therapy CAPD patients. Despite the early fear that diabetic for diabetic patients [1, 2] . In addition, some proposed patients would have a greater peritonitis rate with benefits have been taken into account when choosing atypical bacteria than non-diabetic patients, analysis CAPD for diabetic patients: the slow and sustained of large populations indicated that frequency, clinical ultrafiltration associated with a relative lack of rapid manifestations and management of peritonitis in diafluid and electrolyte changes compared with haemodiabetic and non-diabetic patients are similar [4] [5] [6] . It is lysis; the preservation of residual renal function for a important to remember that almost all patients used longer period than haemodialysis; the possibility of the to be treated with the old connection systems and the intraperitoneal route for insulin administration; an peritonitis rate was high (1 per 6.2 patient/months in easier control of blood pressure; an easier access for diabetic and 1 per 5.3 in non-diabetics patients) [5] . dialytic procedure; and the stability of biochemical No differences in catheter-related infections between parameters [3] .
the two groups were reported [7, 8] . Despite these attractive advantages, some drawbacks In more recent years, a large single centre prospective of CAPD have raised a few concerns regarding the study showed that the peritonitis rate was significantly widespread application of this dialytic modality to the greater in the diabetic group (1.2 vs 0.8 episodes/ diabetic population. Infections are common features patient/year), despite the fact that no difference was of peritoneal dialysis and, since diabetic patients have found in the time from the first episode of infection in a more pronounced immunodepression, they are likely diabetics and non-diabetics [9] . All patients used the to develop a rather more severe infection. Continuous ultraviolet germicidal exchange device for bag connecloss of protein through the dialysate may aggravate a tions. As regards exit site infection, despite some nutritional problem. The most important concern is studies [6 ] which showed an increased rate of exit site the continuous absorption of glucose from the dialysis infection in diabetic patients, a more recent and profluid: this process could be responsible for excessive spective analysis did not find any difference between weight gain, hyperlipidaemia and accelerated atherodiabetic and non-diabetic patients in the first episode sclerosis [3] .
in terms of catheter-related infection and exit site During 20 years of peritoneal dialysis history, infection [9] . Published data on the severity of CAPD peritonitis reported an increased frequency of complications of CAPD peritonitis in diabetic patients. In this study, subcutaneous insulin. Moreover, the frequency of hypoglycaemia episodes is reduced with peritoneal 82% of the peritonitis in diabetic patients required hospital treatment, whilst only 53% of non-diabetic insulin [15] .
Some studies suggested that i.p. insulin therapy is patients with peritonitis were admitted to hospital. In addition, diabetic patients developed recurrence and a associated with lipoprotein profiles of lower atherogenic potential [3] , a reduction in the cholesterol content protracted course more frequently (44%) than nondiabetic patients (15%). This difference was statistically of high density lipoproteins (HDLs) with no change in apolipoproteins A-1 and A-2. Additionally, i.p. significant.
In contrast to these results, Tzamaloukas et al. [11] administration was associated with very low density lipoprotein ( VLDL) triglycerides, VLDL apoliporecorded no difference between diabetic and nondiabetic patients with regard to the persistence of protein B and near normal levels of cholesterol ester transfer. The conclusion of these studies was that i.p. peritonitis for 5 days or more and relapse of peritonitis within 30 days. In this study, the peritonitis rate was insulin was more physiological and corrected a key step in the reverse cholesterol transport in IDDM 1/14.3 patient months for diabetic and 1/14.8 for nondiabetic patients; also the percentage of peritoneal patients.
A recent study [16 ] , however, presented data which catheter removal for peritonitis was no different in the two groups.
contrasted with the previous studies. In a cross-over setting, HDL cholesterol significantly decreased during However, a higher death rate in diabetic patients due to peritonitis episodes was recorded and attributed i.p. treatment, and the LDL/HDL cholesterol ratio was higher. Total cholesterol, LDL cholesterol and to an increased cardiovascular mortality in NIDDM patients because of severe malnutrition during or just triglycerides were again higher during i.p. insulin administration. The conclusions of this study were that after occurrence of the peritonitis. A negative correlation between serum albumin concentration and the although i.p. insulin offers significantly better glycaemic control and insulin sensitivity than subcutaneous myocardial infarction rate in NIDDM patients on chronic dialysis was found.
insulin, the effect on serum lipids is more disadvantageous. Some concerns were raised about the frequency of
Intraperitoneal insulin administration
peritonitis in patients undergoing i.p. insulin treatment.
Despite the fact that the national CAPD registry survey of peritonitis revealed that i.p. insulin administration There is evidence to suggest that intraperitoneal (i.p.) insulin delivery allows faster and consistent absorption was not associated with an increased risk of peritonitis [17] , two European studies demonstrated an increased of insulin. There are several similarities between the absorption kinetics of intraperitoneally administered frequency [18, 19] . Selgas et al. [19] recorded an incidence of peritonitis four times greater in the i.p. group insulin and the normal secretion of insulin by islet cells. Therefore, when CAPD was first introduced, as compared with the subcutaneous insulin group (1/14.4 patient months in the i.p. group and 1/62.4 peritoneal dialysis in diabetic patients was defined as the 'artificial pancreas' [12] . In physiological condi-patient months in the subcutaneous group).
Another problem was the association between i.p. tions, insulin is secreted by islet cells and taken into the portal vein. Thereafter, the liver removes 50-60% insulin and subcapsular liver steatosis. Wanless et al.
[20] described a unique form of hepatic steatosis in of the secreted insulin [13] . Insulin administered into the peritoneal cavity is absorbed by diffusion across which hepatic triglyceride deposition was confined to the subcapsular region of the liver. This finding was the visceral peritoneum into the portal venous circulation. Additionally, direct absorption through the cap-seen only on autopsy examination and was not associated with hepatic abnormalities ante-mortem. All cases sule of the liver has also been reported [14] .
Thus, in this way, i.p. insulin is not delivered directly were diabetic patients on peritoneal dialysis in whom insulin was administered by the i.p. route. into the circulation, and maintains the physiological insulin portal/peripheral ratio of~351; consequently, It was suggested that the insulin and glucose in the dialysis fluid bathing the surface of the liver diffuse the systemic circulation is exposed to a much lower concentration of this hormone [15] . This is likely to across the hepatic capsule. The concentration of insulin and glucose is very high only in the first few layers of be advantageous, since systemic hyperinsulinaemia has been linked to acceleration of atherosclerosis.
hepatocytes and, in this region, free fatty acids are esterified preferentially and lipoprotein production may With the peripheral route of insulin delivery, euglycaemia is achieved at the expense of peripheral hyperin-be suppressed. These conditions greatly favour the steatosic process. sulinaemia, and possibly results in increased hepatic glucose production. Insulin delivered by the i.p. route works directly to reduce hepatic glucose output. Some
Alternative osmotic agents
clinical experience indicates that peritoneal insulin delivery is associated with an improved control of blood glucose. This leads to fewer glycaemic episodes, On average, a CAPD patient typically absorbs 100-150 g of glucose daily during treatment. Apart hence the differences between daily maximum and minimum glucose values are lower compared with from the increased caloric load, in diabetic patients a Diabetes mellitus and peritoneal dialysis 55 higher dose of insulin is required to maintain blood firmed by the USRDS 1994 report [28] . In this large database, the death rate of diabetic haemodialysis glucose control. Every new osmotic agent proposed as an alternative to glucose has claimed to be advanta-patients was lower than that of peritoneal dialysis patients for every subset grouped by age. geous in diabetics. However, few specific studies have been published about alternative osmotic agents in
In these large registries, however, the dialysis dose delivered was not taken into account. A recent analysis diabetic patients.
A glycerol-containing dialysis solution was well tol-comparing two large databases (the CANUSA study for peritoneal dialysis and the RKDP, Minneapolis erated by diabetic patients and its use was associated with an initial decreased requirement for insulin; how-HD data base for haemodialysis) was performed [29] .
Diabetic patients were divided into three age groups ever, this favourable effect was not maintained after 3-4 months [21] . Better control of glucose homeostasis and two levels of Kt/V. The results of 2 year patient survival are shown in Table 1 . These results demonand an improved survival rate were reported in these patients [22] . The use of a glycerol-containing solution strate that comparable survival is achieved in haemoand peritoneal dialysis as long as the therapy dose inevitably leads to an accumulation of glycerol in the blood, and these high levels were associated with is matched. A large Italian regional registry (in Lombardia) confirmed these findings [30] . The relative hyperosmolar symptoms in a few cases [23] . Longterm studies have shown a dramatic increase in the death risk in patients on peritoneal dialysis vs those on haemodialysis, after taking into account the main blood fasting triglyceride concentration after 6 months of treatment. However, this finding was due mainly to co-morbid conditions, did not differ significantly, as estimated by the Cox proportional hazards regression a methodological problem.
Recent studies have proposed the use of a combina-model. Five year survival of diabetic patients was 34%, and no differences were found between haemo-and tion of glycerol and amino acids in the peritoneal dialysis fluid [24] . By using this composite, the concen-peritoneal dialysis in terms of mortality. Our 10 year experience fully confirmed these data ( Figure 1 ). tration of both substances is reduced, thus decreasing the side effects of both. The major advantage of the amino acid-glycerol solution is the reduction in carbo-
Conclusions
hydrate absorption and the independence from insulin for metabolism. A long-term study in the rat and experience in patients showed that the solution can be From 20 years of experience of CAPD, it appears that used safely [24] .
peritoneal dialysis is a viable treatment option for a An amino acid-containing solution could present diabetic patient with end-stage renal disease. The benesome advantages for the diabetic population as compared with the standard glucose solution, mainly High molecular weight Icodextrin appears to be a safe and effective osmotic agent, providing sustained From ref. 29. ultrafiltration. No specific studies so far have been performed in diabetic patients, even in large multicentre investigations [26 ] .
Patients and technique survival
During the early years of CAPD, encouraging results on patients' survival indicated CAPD as the preferred mode of therapy for diabetic patients. Subsequently, large databases have shown discordant results. A historical US prospective sample of 1725 diabetic and 2411 non-diabetic Medicare end-stage renal disease patients from 1986 to 1987 demonstrated that the mortality risk was not statistically different between CAPD and haemodialysis groups for non-diabetic patients, while evidence of a higher adjusted mortality for CAPD compared with haemodialysis was found Fig. 1 . Three year survival of diabetic end-stage renal disease patients treated with peritoneal dialysis in our centre (1990) (1991) (1992) (1993) (1994) (1995) (1996) . amongst diabetic patients [27] . These data were con-15. Bargman JM. The impact of intraperitoneal glucose and insulin fit of i.p. treatment with insulin is reduced by the on the liver. Peritoneal Dial Int 1996; 16 [Suppl 1]: S211-S213 higher incidence of peritonitis episodes. On the con-16. Nevalainen PI, Lahtela JT, Mustonen J, Pasternak A. trary, peritonitis, the main concern of CAPD treat- 
